Market Overview:
The global angina pectoris treatment market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The market is segmented by type, application, and region. The type segment is further divided into antiplatelet agents, beta-adrenergic blocking agents, calcium channel blockers, short & long – acting nitroglycerines, angiotensin-converting enzyme (ACE) inhibitors and anti-ischemic agents. The application segment is divided into hospitals, clinics and other segments. Geographically the market is segmented into North America, Latin America Europe Asia Pacific and Middle East & Africa (MEA). The growth of the global angina pectoris treatment market can be attributed to factors such as rising prevalence of coronary artery diseases (CAD), increasing geriatric population susceptible to CADs and technological advancements in the field of medical devices used for diagnosis.
Product Definition:
Angina pectoris treatment is the medical care given to a person who has angina pectoris. This care may include medicines, procedures, and lifestyle changes.
Antiplatelet Agents:
Antiplatelet agents are a group of medications that reduce the platelets aggregation and prevent thrombus formation. They are used in the treatment of coronary artery disease, cerebrovascular disease, peripheral vascular disease and peripheral ischemia. The antiplatelet drugs can be divided into two types: those that inhibit platelet activation (antithrombotic) and those that inhibit platelet clumping (anticoagulant).
Beta-Adrenergic Blocking Agents:
Beta-adrenergic blocking agents are used to treat life-threatening symptoms of cardiac arrest. The most common symptom is shortness of breath, which occurs when the body cannot produce enough oxygen for its tissues due to decreased activity or blockage in the lungs or heart.
Global Beta-Adrenergic Blocking Agents.
Application Insights:
The other application segment held the largest share of over 60.0% in 2017. The growing prevalence of chronic diseases, such as diabetes and cardiac disorders, is anticipated to boost the demand for effective angina pectoris treatment drugs in this segment. Moreover, increasing awareness about these diseases and availability of advanced treatment options are expected to further drive the market during the forecast period.
Clinic held a significant share owing to rising awareness among patients regarding timely diagnosis and treatment for various cardiovascular conditions along with advancements in technology that have led to increased accessibility of cardiology clinics across developed nations like U.S.
Regional Analysis:
North America dominated the global market in 2017 owing to favorable reimbursement policies, increasing prevalence of cardiovascular diseases, and rising awareness about treatment options. Moreover, a high number of product launches is also expected to drive regional growth over the forecast period. For instance, in May 2016 Merck & Co., Inc. launched its new drug Cardene for treating hypertension and angina pectoris; it is an anti-arrhythmic agent that blocks beta-2 adrenergic receptors which reduces blood pressure and heart rate.
Growth Factors:
- Increasing incidence of angina pectoris
- Growing geriatric population
- Rising prevalence of obesity and diabetes
- Technological advancements in the field of angina pectoris treatment 5. increasing healthcare expenditure
Scope Of The Report
Report Attributes
Report Details
Report Title
Angina Pectoris Treatment Market Research Report
By Type
Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long – Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) Inhibitors, Anti-Ischemic Agents
By Application
Hospitals, Clinic, Other
By Companies
Abbott Laboratories Inc., Astra Zeneca plc, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Forest Laboratories Inc, Gilead Sciences, Inc, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Abbott Laboratories Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
224
Number of Tables & Figures
157
Customization Available
Yes, the report can be customized as per your need.
Global Angina Pectoris Treatment Market Report Segments:
The global Angina Pectoris Treatment market is segmented on the basis of:
Types
Antiplatelet Agents, Beta-Adrenergic Blocking Agents, Calcium Channel Blockers, Short & Long – Acting Nitroglycerines, Angiotensin-Converting Enzyme (ACE) Inhibitors, Anti-Ischemic Agents
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott Laboratories Inc.
- Astra Zeneca plc
- Bayer AG
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- Forest Laboratories Inc
- Gilead Sciences, Inc
- GlaxoSmithKline plc
- Novartis AG
- Pfizer Inc.
- Abbott Laboratories Inc.
Highlights of The Angina Pectoris Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Antiplatelet Agents
- Beta-Adrenergic Blocking Agents
- Calcium Channel Blockers
- Short & Long – Acting Nitroglycerines
- Angiotensin-Converting Enzyme (ACE) Inhibitors
- Anti-Ischemic Agents
- By Application:
- Hospitals
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Angina Pectoris Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Angina Pectoris Treatment is the medical treatment of chest pain due to a blocked coronary artery.
Some of the major players in the angina pectoris treatment market are Abbott Laboratories Inc., Astra Zeneca plc, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Forest Laboratories Inc, Gilead Sciences, Inc, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Abbott Laboratories Inc..
The angina pectoris treatment market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Angina Pectoris Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Angina Pectoris Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Angina Pectoris Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Angina Pectoris Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Angina Pectoris Treatment Market Size & Forecast, 2020-2028
4.5.1 Angina Pectoris Treatment Market Size and Y-o-Y Growth
4.5.2 Angina Pectoris Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Antiplatelet Agents
5.2.2 Beta-Adrenergic Blocking Agents
5.2.3 Calcium Channel Blockers
5.2.4 Short & Long – Acting Nitroglycerines
5.2.5 Angiotensin-Converting Enzyme (ACE) Inhibitors
5.2.6 Anti-Ischemic Agents
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinic
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Angina Pectoris Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Angina Pectoris Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Antiplatelet Agents
9.6.2 Beta-Adrenergic Blocking Agents
9.6.3 Calcium Channel Blockers
9.6.4 Short & Long – Acting Nitroglycerines
9.6.5 Angiotensin-Converting Enzyme (ACE) Inhibitors
9.6.6 Anti-Ischemic Agents
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinic
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Antiplatelet Agents
10.6.2 Beta-Adrenergic Blocking Agents
10.6.3 Calcium Channel Blockers
10.6.4 Short & Long – Acting Nitroglycerines
10.6.5 Angiotensin-Converting Enzyme (ACE) Inhibitors
10.6.6 Anti-Ischemic Agents
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinic
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Antiplatelet Agents
11.6.2 Beta-Adrenergic Blocking Agents
11.6.3 Calcium Channel Blockers
11.6.4 Short & Long – Acting Nitroglycerines
11.6.5 Angiotensin-Converting Enzyme (ACE) Inhibitors
11.6.6 Anti-Ischemic Agents
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinic
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Antiplatelet Agents
12.6.2 Beta-Adrenergic Blocking Agents
12.6.3 Calcium Channel Blockers
12.6.4 Short & Long – Acting Nitroglycerines
12.6.5 Angiotensin-Converting Enzyme (ACE) Inhibitors
12.6.6 Anti-Ischemic Agents
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinic
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Antiplatelet Agents
13.6.2 Beta-Adrenergic Blocking Agents
13.6.3 Calcium Channel Blockers
13.6.4 Short & Long – Acting Nitroglycerines
13.6.5 Angiotensin-Converting Enzyme (ACE) Inhibitors
13.6.6 Anti-Ischemic Agents
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinic
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Angina Pectoris Treatment Market: Competitive Dashboard
14.2 Global Angina Pectoris Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbott Laboratories Inc.
14.3.2 Astra Zeneca plc
14.3.3 Bayer AG
14.3.4 Bristol-Myers Squibb Company
14.3.5 F. Hoffmann-La Roche Ltd
14.3.6 Forest Laboratories Inc
14.3.7 Gilead Sciences, Inc
14.3.8 GlaxoSmithKline plc
14.3.9 Novartis AG
14.3.10 Pfizer Inc.
14.3.11 Abbott Laboratories Inc.
